Melanoma study pulled before start: local attack on resistant tumors never tested
NCT ID NCT07092410
First seen Apr 28, 2026 · Last updated Apr 28, 2026
Summary
This study planned to test whether adding surgery, radiation, or electrochemotherapy could help control melanoma spots that did not shrink with the targeted drug combo encorafenib + binimetinib. It was designed for adults with BRAF-mutated melanoma who had been on the drugs for at least 3 months. However, the study was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA BRAF V600E/K MUTATED are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.